川宁生物(301301) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 1,087,400,237.93, a decrease of 13.76% year-over-year, and year-to-date revenue was CNY 3,435,984,280.40, down 22.90% compared to the same period last year[6] - Net profit attributable to shareholders was CNY 156,534,899.95, a decline of 49.44% year-over-year, with year-to-date net profit at CNY 611,393,152.05, down 43.17%[6] - Basic earnings per share decreased by 50.00% to CNY 0.07 for Q3 2025, and year-to-date earnings per share were CNY 0.27, down 43.75%[6] - Total operating revenue for the current period was ¥3,435,984,280.40, a decrease of 22.9% compared to ¥4,456,265,553.38 in the previous period[25] - Net profit for the current period was ¥610,903,946.61, a decline of 43.3% from ¥1,075,957,079.13 in the previous period[26] - Basic and diluted earnings per share were both ¥0.27, down from ¥0.48 in the previous period[27] Cash Flow - Cash flow from operating activities for the year-to-date period was CNY 570,941,265.31, a decrease of 34.77% compared to the previous year[6] - Cash flow from operating activities was ¥2,759,760,332.74, a decrease from ¥3,108,948,836.09 in the previous period[29] - The net cash flow from operating activities was $570,941,265.31, a decrease of 34.7% compared to $875,259,669.44 in the previous period[30] - Cash received from tax refunds was $2,932,581.56, up from $1,185,342.77 in the previous period[30] - Cash received from other operating activities was $64,561,162.12, an increase from $55,526,536.86 year-over-year[30] - Cash paid to employees was $371,438,880.45, compared to $338,659,024.58 in the previous period, reflecting a 9.7% increase[30] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,330,777,681.39, a decrease of 2.11% from the previous year-end[6] - Total current assets decreased from ¥4,144,223,873.54 to ¥4,021,681,016.89, a decline of about 3.0%[21] - Total non-current assets decreased from ¥6,409,356,087.63 to ¥6,309,096,664.50, a reduction of approximately 1.6%[21] - Total liabilities decreased to ¥2,379,267,730.87 from ¥2,637,164,117.24, reflecting a reduction of 9.8%[22] - Non-current liabilities decreased to ¥578,203,091.88 from ¥689,629,227.58, a decline of 16.1%[22] Expenses - Research and development expenses increased by 89.80% to CNY 83,635,566.63, reflecting higher investment in new product development[13] - Management expenses rose by 30.48% to CNY 157,758,113.09 due to increased costs associated with new product trials[13] - The company reported a significant increase in research and development expenses to ¥83,635,566.63, up 89.8% from ¥44,066,130.04 in the previous period[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 51,300[15] - Sichuan Kelun Pharmaceutical Co., Ltd. holds 70.40% of shares, totaling 1,569,887,643 shares[15] Financing Activities - The company’s short-term borrowings increased by 71.37% to CNY 360,139,102.22, indicating a rise in financing needs[12] - Short-term borrowings increased from ¥210,152,563.90 to ¥360,139,102.22, an increase of approximately 71.4%[21] - The company issued a technology innovation bond with a total scale of ¥200 million at a coupon rate of 1.99%[18] Other Income - The company received government subsidies amounting to CNY 15,656,604.43, an increase of 180.48% compared to the previous year[13] - Other income for the current period was ¥15,656,604.43, compared to ¥5,582,166.60 in the previous period, indicating a substantial increase[25]